Max Biopharma, Inc.
Los Angeles, CA · Biotech · Private
Semi-synthetic oxysterol small molecules (Oxy210) that modulate Hedgehog and TGF-β signaling pathways to treat liver fibrosis and NASH
maxbiopharma.com →- Grants
- $11M
- 14 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 13
- 2 granted · 11 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20152017201920212023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Synthesis of bone-selective osteogenic oxysterols | $448,646 | |
| Federal grant | Department of Health and Human Services · Phase II · Synthesis of bone selective osteogenic oxysterols | $899,267 | |
| Federal grant | Department of Health and Human Services · Phase II · Design and synthesis of bone-selective osteogenic oxysterol-bisphosphonate analogues | $498,960 | |
| Federal grant | Department of Health and Human Services · Phase II · Synthesis of bone-selective osteogenic oxysterols | $450,621 | |
| Federal grant | Department of Health and Human Services · Phase II · Design and synthesis of bone-selective osteogenic oxysterol-bisphosphonate analogues | $499,690 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical Development of Oxy200 for the Treatment of Osteoporosis | $1,950,018 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical Development of Oxy200 for the Treatment of Osteoporosis | $975,009 | |
| Federal grant | Department of Health and Human Services · Phase I · Inhibition of Liver Fibrosis by Oxysterol Drug Candidates in a Mouse Model of NASH | $223,696 | |
| Federal grant | Department of Health and Human Services · Phase II · Therapeutic Development of Osteogenic Oxysterol, Oxy133, for Spine Fusion | $1,707,540 | |
| Federal grant | Department of Health and Human Services · Phase I · Effect of a semi-synthetic oxysterol drug candidate, Oxy210, on atherosclerosis in a mouse model of NASH | $320,724 | |
| Federal grant | Department of Health and Human Services · Phase I · An oxysterol drug candidate, Oxy210, for inhibition of pulmonary fibrosis through targeting hedgehog and TGFβ signaling | $318,089 | |
| Federal grant | Department of Health and Human Services · Phase II · Therapeutic Development of Osteogenic Oxysterol, Oxy133, for Spine Fusion | $852,387 | |
| Federal grant | Department of Health and Human Services · Phase II · Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitis | $896,990 | |
| Federal grant | Department of Health and Human Services · Phase II · Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitis | $889,701 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1573 | NANORED LLC | — | — |
| 1574 | GENELUX Corp | — | $24M |
| 1575 | RUMI SCIENTIFIC, INC. | — | — |
| 1576 | Max Biopharma, Inc. | — | — |
| 1577 | Neurocarrus Inc. | — | — |
| 1578 | ANOVAC, INC. | — | — |
| 1579 | Vesalius Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Methods And Compositions For Treating Fibrotic Diseasesapplication
- Oxysterol Compounds And Uses Thereofapplication
- Oxysterols And Hedgehog Signalinggranted
- Oxysterols And Hedgehog Signalingapplication
- Oxysterols And Hedgehog Signalinggranted
- Oxysterol Compounds And Uses Thereofapplication
- Methods And Compositions For Treating Fibrotic Diseasesapplication
- Oxysterols And Hedgehog Signalingapplication
- Oxysterols And Hedgehog Signalingapplication
- Oxysterols And Hedgehog Signalingapplication
- Oxysterol Compounds And Uses Thereofapplication
- Oxysterols And Hedgehog Signalingapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.